Why the study?
Does restoration of progenitor cell function rescue anthracycline cardiomyopathy?
Does restoration of progenitor cell function rescue anthracycline cardiomyopathy?
Autologous cardiac progenitor cells may offer a potential therapeutic strategy for preventing or managing anthracycline-induced heart failure.
May support progenitor cell therapy trials in anthracycline cardiomyopathy; leaves open clinical efficacy.
Our results raise the possibility that autologous CPCs can be obtained before antineoplastic drugs are given to cancer patients and subsequently administered to individuals who are particularly sensitive to the cardiotoxicity of these agents for prevention or management of heart failure.
No takes yet. Share an insight, caveat, or question.
Angelis et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: